dabigatran has been researched along with darunavir in 2 studies
| Studies (dabigatran) | Trials (dabigatran) | Recent Studies (post-2010) (dabigatran) | Studies (darunavir) | Trials (darunavir) | Recent Studies (post-2010) (darunavir) |
|---|---|---|---|---|---|
| 3,887 | 261 | 3,490 | 1,148 | 224 | 780 |
| Protein | Taxonomy | dabigatran (IC50) | darunavir (IC50) |
|---|---|---|---|
| Chain A, HIV-1 protease | Human immunodeficiency virus 1 | 0.0028 | |
| Chain B, HIV-1 protease | Human immunodeficiency virus 1 | 0.0028 | |
| Chain A, HIV-1 protease | Human immunodeficiency virus 1 | 0.0028 | |
| Chain B, HIV-1 protease | Human immunodeficiency virus 1 | 0.0028 | |
| ATP-dependent translocase ABCB1 | Homo sapiens (human) | 6.6 | |
| Protease | Human immunodeficiency virus 1 | 0.063 | |
| Protease | Human immunodeficiency virus 1 | 0.0014 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fulco, PP; Higginson, RT; Kakadiya, PP | 1 |
| Betti, M; Danzi, GB; Dellanoce, C; Giorgi-Pierfranceschi, M; Morandini, R; Palareti, G; Pan, A; Paoletti, O; Prandoni, P; Tala, M; Testa, S | 1 |
2 other study(ies) available for dabigatran and darunavir
| Article | Year |
|---|---|
Ritonavir-Boosted Protease Inhibitors but Not Cobicistat Appear Safe in HIV-Positive Patients Ingesting Dabigatran.
Topics: Aged; Anti-HIV Agents; Cobicistat; Dabigatran; Darunavir; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Male; Ritonavir | 2018 |
Direct oral anticoagulant plasma levels' striking increase in severe COVID-19 respiratory syndrome patients treated with antiviral agents: The Cremona experience.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antithrombins; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; Dabigatran; Darunavir; Drug Interactions; Drug Monitoring; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Italy; Lopinavir; Male; Pandemics; Patient Safety; Pneumonia, Viral; Pyrazoles; Pyridines; Pyridones; Risk Assessment; Risk Factors; Ritonavir; SARS-CoV-2; Severity of Illness Index; Thiazoles | 2020 |